MB 272
Alternative Names: GS-0272; MB-272Latest Information Update: 20 Oct 2023
At a glance
- Originator University of Oxford
- Developer MiroBio
- Class Antibodies; Antirheumatics
- Mechanism of Action BTLA protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- Phase I Autoimmune disorders; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 20 Oct 2023 Phase-I clinical trials in Rheumatoid arthritis in USA (SC) (NCT06031415)
- 28 Sep 2023 Phase-I clinical trials in Systemic lupus erythematosus in USA (SC) (NCT06031415)
- 14 Sep 2023 Gilead Sciences plans a phase I MARASLE trial for Rheumatoid arthritis or Systemic lupus erythematous in September 2023 (SC) (NCT06031415)